November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
8 citations
,
January 2008 in “Annals of Dermatology” Combining Cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata.
6 citations
,
January 2012 in “Journal of Biomedicine and Biotechnology” Ustekinumab might work for severe psoriasis, but more research is needed to be sure.
April 2023 in “Dermatology practical & conceptual” Tacrolimus solution is effective and well-tolerated for treating inflammatory scalp conditions.
June 2011 in “Journal of clinical and experimental investigations” Oral zinc sulphate is an effective and safe treatment for thallium poisoning.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
6 citations
,
December 2022 in “Anais Brasileiros de Dermatologia” 1 citations
,
January 2020 in “Skin Appendage Disorders” Treatment with methotrexate and prednisolone led to complete hair regrowth and no relapse for 2 years.
1 citations
,
December 2025 in “Journal of the American Academy of Dermatology” 2 citations
,
January 2023 in “Uro” UHP-sCESr is as effective as HESr for treating BPH symptoms.
5 citations
,
August 2014 in “Australasian journal of dermatology” Sorafenib can cause delayed skin problems, so patients need careful monitoring.
October 2025 in “International Journal of Risk & Safety in Medicine” Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
37 citations
,
October 2006 in “Steroids” New sulfur-containing steroid analogs show promise for more targeted medical treatments.
20 citations
,
June 2024 in “Journal of Autoimmunity” Inflammation in rheumatoid arthritis increases steroid activation in cells, reducing inflammation.
July 2022 in “medRxiv (Cold Spring Harbor Laboratory)” Satoyoshi syndrome is likely an autoimmune disease that mainly affects young women and improves with immune-related treatments.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
May 2026 in “Reactions Weekly”
5 citations
,
June 2015 in “British Journal of Dermatology” A certain medication improved severe itching in a boy with liver and bowel disease by reducing histamine levels, suggesting a new treatment target.
November 2021 in “European Heart Journal Supplements” A woman with lupus had right heart failure due to blood clots in her lungs, but treatment improved her condition.
September 2018 in “Reactions Weekly” Two women had skin reactions from a hair loss treatment and got better after stopping use.
January 2021 in “International journal of basic and clinical pharmacology” Hydroxychloroquine is less effective than betamethasone oral mini pulse therapy for treating alopecia areata.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
1 citations
,
October 2022 in “Rheumatology” RHUPUS should be considered in children with deforming arthritis.
16 citations
,
October 2013 in “Anais Brasileiros de Dermatologia” Scalp condition healed with prednisone and tacrolimus.
January 2024 in “Archives of dermatological research” Both treatments for alopecia areata showed similar modest effectiveness.
44 citations
,
October 2020 in “Arthritis Care & Research” Choosing the right tools is crucial for accurately measuring lupus activity and damage.
The 1298CC genotype in RA patients leads to higher methotrexate toxicity, while the 1298AA genotype results in better treatment response.